Pfizer Inc. (NYSE:PFE) Stake Boosted by Drystone LLC

Drystone LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 162,688 shares of the biopharmaceutical company's stock after purchasing an additional 16,888 shares during the quarter. Pfizer comprises 4.1% of Drystone LLC's portfolio, making the stock its 11th largest position. Drystone LLC's holdings in Pfizer were worth $4,123,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the period. Achmea Investment Management B.V. acquired a new position in Pfizer during the 4th quarter valued at about $2,812,000. Madison Investment Advisors LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $5,360,000. Finally, Greatmark Investment Partners Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $230,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.5%

Shares of Pfizer stock traded down $0.13 during trading on Friday, hitting $25.65. The stock had a trading volume of 34,838,317 shares, compared to its average volume of 41,846,522. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $145.83 billion, a PE ratio of 18.59, a P/E/G ratio of 0.94 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a 50 day simple moving average of $23.89 and a 200 day simple moving average of $24.79.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the company earned $0.82 earnings per share. The company's revenue for the quarter was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.71%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Morgan Stanley boosted their target price on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Citigroup lifted their price target on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. Redburn Atlantic decreased their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.